Pringy Cedex

• A Study Evaluating the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered-Dose Inhaler on Cardiopulmonary Outcomes in C … Recruiting
  2023-507407-59-00 5 2024-07-04 Chronic Obstructive Pulmonary Disease (COPD)
• FIRST-NEC - A multicenter phase II study evaluating the efficacy and safety of the combination of durvalumab (MEDI 4736) with etoposide and … Recruiting
  2023-506590-35-00 4 2024-06-13 Large-Cell NeuroEndocrine Carcinoma of the lung
• MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal a … Recruiting
  2023-505436-35-00 5 2024-06-03 Untreated FLIPI 2-5 Follicular Lymphoma
• Evaluation of EXL01 a new Live Biotherapeutic Product to prevent recurrence of Clostridioides difficile infection in high-risk patients. LIV … Recruiting
  2023-506232-32-00 9 2024-04-08 Multiple recurrences of Clostridioides difficile infection treated wit
• Impact of rifampicin in treatment outcome of Cutibacterium spp. prosthetic joint infections - RIFACute Recruiting
  2022-502974-18-00 10 2023-11-27 C. spp. prosthetic joint infection
• Randomized open-label controlled trial evaluating a single-dose intravenous Dalbavancin versus standard antibiotic therapy during catheterre … Recruiting
  2024-514952-34-00 5 2023-06-23 Catheter related bloodstream infections due to Staphylococcus aureus
• Benefit of transplantation after Complete Response In Patients with T-cell lymphoma Recruiting
  2022-501710-62-02 6 2023-06-07 Peripheral T-cell lymphoma (PTCL)
• TRAK-ER_A randomised trial of early detection of molecular relapse with circulating tumour DNA tracking and treatment with palbociclib plus … Recruiting
  2024-517414-15-00 4 2023-01-25 ER positive HER2 negative breast cancer
• Baricitinib in patients with relapsing or naïve dermatomyositis (BIRD) Recruiting
  2024-511899-32-00 10 2022-08-31 Dermatomyositis; Baricitinib in patients with relapsing or naïve derma
• Randomised phase III trial of ADT +/- darolutamide in frail men with castration-naïve de novo metastatic prostate cancer Recruiting
  2022-502425-18-00 5 2022-04-19 Adenocarcinoma of the prostate
• Study evaluating the tailored management of locally-advanced rectal carcinoma Recruiting
  2024-511609-44-00 10 2022-02-03 Rectum cancer
• IFM2020-05-BENEFIT-Multicenter Open label Phase 3 study of Isatuximab plus Lenalidomide and Dexamethasone with/without Bortezomib in the Tre … Recruiting
  2024-517215-67-00 5 2021-06-11 Newly diagnosed Non-Frail transplant Ineligible Multiple Myeloma elder
• Short Treatment With Omalizumab for Severe Asthma (SHORTEN) Recruiting
  2024-513427-17-00 6 2021-05-20 Well controlled severe allergic asthma
• Randomized phase 3 trial comparing FOLFOX to gemcitabine in metastatic first-line in patients with pancreatic adenocarcinoma and non-fit for … Recruiting
  2024-511904-18-00 10 2020-07-08 Pancreatic adenocarcinoma (PAC)
• CLAZI : CLArithromycin versus AZIthromycin in the treatment of Mycobacterium avium complex pulmonary infections: A randomized prospective co … Recruiting
  2024-518578-15-00 5 2018-02-05 Is to demonstrate a non inferior efficacy of azithromycin and so the p
• GRAALL2014 Recruiting
  2024-516103-16-00 4 2015-12-04 Acute Lymphoblastic Leukemia (ALL) in younger adults (18-59 years)
• Phase 2/3 Randomized Study of INBRX-106 Add-on to Pembrolizumab in First-Line PD-L1 CPS ≥20 R/M HNSCC (HexAgon-HN) Ended recruitment
  2024-515538-34-00 10 2025-02-27 Head and Neck Squamous Cell Carcinoma
• Management of Anticoagulant Therapy monitored by an implantable device with telecardiology in patients with Acute Coronary Syndrome associat … Ended recruitment
  2024-515433-15-02 6 2025-01-29 acute coronary syndrome
• DAPAgliflozine to attenuate cardiac RemOdeling afTEr aCuTe myOcardial infarction Ended recruitment
  2024-511882-13-01 5 2024-11-19 Cardiac failure
• MLS-101-901: An Open-Label Extension Study to Assess the Long-Term Safety, Efficacy, and Tolerability of Lorundrostat in Subjects with Hyper … Ended recruitment
  2023-508670-28-00 5 2024-08-26 Hypertension
• TocilizuMab discontinuAtion in GIant Cell Arteritis Ended recruitment
  2023-505515-21-00 5 2024-04-02 Giant Cell Arteritis
• PRODIGE 85 (FFCD 1804) – KANALRAD Prospective randomized phase III study evaluating induction chemotherapy (modified DCF 4 cycles) followed … Ended recruitment
  2023-505972-32-00 5 2024-02-26 locally advanced anal squamous cell carcinoma
• Study of safety and efficacy of ONUREG in combination with VENETOCLAX in higher-risk myelodysplastic syndromes ineligible for allogenic tran … Ended recruitment
  2024-514876-41-00 9 2023-12-06 Higher-risk myelodysplastic syndromes untreated and ineligible for all
• Study of safety and efficacy of Venetoclax in combination with Vidaza (Azacitidine) in higher-risk Chronic Myelomonocytic Leukemia (CMML) Ended recruitment
  2024-514878-53-00 4 2023-10-04 HMA-naïve, higher-risk (HR, defined as CPSS-mol risk intermediate-2 or

Showing 25–48 of 98 trials